Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats
Abstract Background Subcutaneous ureteral bypass (SUB) device placement is an increasingly popular treatment option for decompression of ureteral obstruction in cats. Mineralization occlusion of the device occurs in a minority of cases but is the most common complication. Objective To evaluate a 2%...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-09-01
|
| Series: | Journal of Veterinary Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jvim.15582 |
| _version_ | 1828323653838700544 |
|---|---|
| author | Colin Chik Allyson C. Berent Chick W. Weisse Marcia Ryder |
| author_facet | Colin Chik Allyson C. Berent Chick W. Weisse Marcia Ryder |
| author_sort | Colin Chik |
| collection | DOAJ |
| description | Abstract Background Subcutaneous ureteral bypass (SUB) device placement is an increasingly popular treatment option for decompression of ureteral obstruction in cats. Mineralization occlusion of the device occurs in a minority of cases but is the most common complication. Objective To evaluate a 2% tetrasodium ethylenediaminetetraacetic acid (tEDTA) solution for treatment of mineralization occlusion in cats with SUBs. Animals Six client‐owned cats (8 obstructed devices). Methods Case series. Each cat was found to have device occlusion based on a combination of ultrasound examination, SUB irrigation, and failure to identify another cause of device obstruction. Each SUB was drained, irrigated using sterile saline, and infused with 1‐2 mL of 2% tEDTA solution. Success was defined as normalization of flow during subsequent ultrasound visualization while irrigating. The volume and frequency of tEDTA instillations, time to achieve device patency, follow‐up biochemical and ultrasound findings, and future reobstruction events were recorded. Results Resolution of mineralization was documented in all 8 SUBs. Reobstruction events occurred in 2 cats, all of which resolved after additional tEDTA infusions, but 1 cat ultimately required device exchange at 356 days from the first tEDTA infusion. In 1 cat, a single infusion was prematurely discontinued because of persistent pelvic dilatation after 1.25 mL of tEDTA had been instilled. No complications were observed. Conclusions and Clinical Importance Tetrasodium EDTA infusions can be safely considered as a treatment option for mineralized SUB devices in cats. This solution was easily infused, well tolerated, and avoided the need for SUB device exchange in the majority of cats in which it was used. |
| first_indexed | 2024-04-13T18:55:27Z |
| format | Article |
| id | doaj.art-6bbac4fa56554b9bac4c6efb9e84d1a6 |
| institution | Directory Open Access Journal |
| issn | 0891-6640 1939-1676 |
| language | English |
| last_indexed | 2024-04-13T18:55:27Z |
| publishDate | 2019-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Veterinary Internal Medicine |
| spelling | doaj.art-6bbac4fa56554b9bac4c6efb9e84d1a62022-12-22T02:34:16ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762019-09-013352124213210.1111/jvim.15582Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in catsColin Chik0Allyson C. Berent1Chick W. Weisse2Marcia Ryder3Department of Diagnostic Imaging and Interventional Radiology The Animal Medical Center New York New YorkDepartment of Diagnostic Imaging and Interventional Radiology The Animal Medical Center New York New YorkDepartment of Diagnostic Imaging and Interventional Radiology The Animal Medical Center New York New YorkRyder Science, Inc. Medical Biofilm Research Brentwood TennesseeAbstract Background Subcutaneous ureteral bypass (SUB) device placement is an increasingly popular treatment option for decompression of ureteral obstruction in cats. Mineralization occlusion of the device occurs in a minority of cases but is the most common complication. Objective To evaluate a 2% tetrasodium ethylenediaminetetraacetic acid (tEDTA) solution for treatment of mineralization occlusion in cats with SUBs. Animals Six client‐owned cats (8 obstructed devices). Methods Case series. Each cat was found to have device occlusion based on a combination of ultrasound examination, SUB irrigation, and failure to identify another cause of device obstruction. Each SUB was drained, irrigated using sterile saline, and infused with 1‐2 mL of 2% tEDTA solution. Success was defined as normalization of flow during subsequent ultrasound visualization while irrigating. The volume and frequency of tEDTA instillations, time to achieve device patency, follow‐up biochemical and ultrasound findings, and future reobstruction events were recorded. Results Resolution of mineralization was documented in all 8 SUBs. Reobstruction events occurred in 2 cats, all of which resolved after additional tEDTA infusions, but 1 cat ultimately required device exchange at 356 days from the first tEDTA infusion. In 1 cat, a single infusion was prematurely discontinued because of persistent pelvic dilatation after 1.25 mL of tEDTA had been instilled. No complications were observed. Conclusions and Clinical Importance Tetrasodium EDTA infusions can be safely considered as a treatment option for mineralized SUB devices in cats. This solution was easily infused, well tolerated, and avoided the need for SUB device exchange in the majority of cats in which it was used.https://doi.org/10.1111/jvim.15582kidneyrenal calculirenal/urinary tractureteral calculiureteral obstructionureteral surgery |
| spellingShingle | Colin Chik Allyson C. Berent Chick W. Weisse Marcia Ryder Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats Journal of Veterinary Internal Medicine kidney renal calculi renal/urinary tract ureteral calculi ureteral obstruction ureteral surgery |
| title | Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats |
| title_full | Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats |
| title_fullStr | Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats |
| title_full_unstemmed | Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats |
| title_short | Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats |
| title_sort | therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats |
| topic | kidney renal calculi renal/urinary tract ureteral calculi ureteral obstruction ureteral surgery |
| url | https://doi.org/10.1111/jvim.15582 |
| work_keys_str_mv | AT colinchik therapeuticuseoftetrasodiumethylenediaminetetraaceticacidsolutionfortreatmentofsubcutaneousureteralbypassdevicemineralizationincats AT allysoncberent therapeuticuseoftetrasodiumethylenediaminetetraaceticacidsolutionfortreatmentofsubcutaneousureteralbypassdevicemineralizationincats AT chickwweisse therapeuticuseoftetrasodiumethylenediaminetetraaceticacidsolutionfortreatmentofsubcutaneousureteralbypassdevicemineralizationincats AT marciaryder therapeuticuseoftetrasodiumethylenediaminetetraaceticacidsolutionfortreatmentofsubcutaneousureteralbypassdevicemineralizationincats |